The FDA has granted Schering-Plough marketing approval for PEGintron and Rebetol combination therapy for use in previously untreated patients three years of age and older with chronic hepatitis C. This represents the first and only approved peginterferon in combination with ribavirin for treating pediatric hepatitis C. It is estimated that approximately 130,000 children in the U.S. are infected with the hepatitis C virus (HCV); the most common mode of HCV infection for pediatric patients today i...